A detailed history of Royal Bank Of Canada transactions in Acumen Pharmaceuticals, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 5,941 shares of ABOS stock, worth $10,634. This represents 0.0% of its overall portfolio holdings.

Number of Shares
5,941
Previous 4,045 46.87%
Holding current value
$10,634
Previous $9,000 55.56%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$2.22 - $3.54 $4,209 - $6,711
1,896 Added 46.87%
5,941 $14,000
Q2 2024

Aug 14, 2024

BUY
$2.14 - $4.01 $8,438 - $15,811
3,943 Added 3865.69%
4,045 $9,000
Q1 2024

Nov 05, 2024

SELL
$2.97 - $4.64 $11,710 - $18,295
-3,943 Reduced 97.48%
102 $0
Q1 2024

May 15, 2024

SELL
$2.97 - $4.64 $1,681 - $2,626
-566 Reduced 84.73%
102 $0
Q4 2023

Feb 14, 2024

BUY
$1.86 - $4.48 $1,052 - $2,535
566 Added 554.9%
668 $2,000
Q3 2023

Nov 14, 2023

SELL
$4.15 - $9.72 $805 - $1,885
-194 Reduced 65.54%
102 $0
Q2 2023

Aug 14, 2023

SELL
$3.59 - $6.59 $315 - $579
-88 Reduced 22.92%
296 $1,000
Q1 2023

May 15, 2023

BUY
$3.75 - $6.65 $1,421 - $2,520
379 Added 7580.0%
384 $1,000
Q4 2022

Feb 14, 2023

SELL
$4.81 - $10.17 $221 - $467
-46 Reduced 90.2%
5 $0
Q3 2022

Nov 14, 2022

BUY
$4.44 - $10.48 $226 - $534
51 New
51 $1,000
Q2 2022

Aug 15, 2022

SELL
$3.08 - $4.88 $5,356 - $8,486
-1,739 Closed
0 $0
Q1 2022

May 16, 2022

SELL
$3.91 - $6.73 $2,467 - $4,246
-631 Reduced 26.62%
1,739 $7,000
Q4 2021

Feb 14, 2022

BUY
$6.54 - $15.31 $8,299 - $19,428
1,269 Added 115.26%
2,370 $16,000
Q3 2021

Nov 15, 2021

BUY
$14.5 - $20.28 $15,964 - $22,328
1,101 New
1,101 $16,000

Others Institutions Holding ABOS

About Acumen Pharmaceuticals, Inc.


  • Ticker ABOS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,503,100
  • Market Cap $72.5M
  • Description
  • Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Ph...
More about ABOS
Track This Portfolio

Track Royal Bank Of Canada Portfolio

Follow Royal Bank Of Canada and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.